- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 28, 2023Robins Kaplan LLP Announces 2023 Leadership Council on Legal Diversity (LCLD) Fellow and Pathfinder
March 22, 2023Benchmark Litigation Names Robins Kaplan 2023 Minnesota Law Firm of the Year
March 16, 2023Second Circuit Affirms Record $5.6 Billion Recovery in Antitrust Case
March 29-30, 2023ACI Managed Care Disputes and Litigation
April 3, 2023Conference of Tribal Lending Commissioners
April 11-13, 2023Mass Torts Made Perfect Seminar
March 2023Unintended Consequences of Banning Noncompete Agreements
March 26, 2023What I’ll Be Watching for in the Amgen Oral Arguments
March 13, 2023The Antitrust Case that Could Reshape Professional Golf
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Managing IP Recognizes Robins Kaplan For Patent Contentious and PTAB Litigation in 2022
July 6, 2022
Robins Kaplan LLP is pleased to announce that it was named a “Highly Recommended Firm” for patent contentious litigation in Minnesota by Managing Intellectual Property, a recognition shared with just two other firms in the state. The magazine also recognized the firm for PTAB litigation, nationally.
According to Managing IP, firm rankings are based on a weighted system of peer and client feedback, combined with submissions analysis and independent research. For this year’s rankings, Managing IP considered key results that the firm obtained on behalf of clients between the fall of 2020 and 2021. Select patent litigation highlights included:
- Endonovo Therapeutics, Inc. v. Orthocore Medical, Inc.: Robins Kaplan LLP served as lead defense counsel representing Orthocore Medical, Inc., and its corporate parent Caerus Corporation in a patent infringement suit related to pulse electromagnetic field (PEMF) medical and veterinary devices. In December 2020, through aggressive representation, we secured a complete dismissal with prejudice of all claims asserted against our clients, without any settlement payment or other concessions.
- Collegium Pharmaceutical Inc. v. Teva Pharmaceuticals USA: In September 2020, on behalf of its client Collegium, Robins Kaplan brought to resolution a significant patent litigation against Teva related to Xtampza® ER, Collegium’s brand abuse-deterrent oxycodone with annual sales in excess of $100 million. Under the settlement, Teva agreed to a consent judgment confirming that its proposed generic products infringe Collegium’s 14 asserted Orange Book-listed patents. Collegium also agreed to grant Teva a license to market its generic version of Xtampza® ER in the United States beginning on or after September 2, 2033.
- TQ Delta, LLC v. 2Wire: In May 2019 and January 2020, on behalf of its client TQ Delta, Robins Kaplan, as conflicts counsel conducting the investigation and trial presentation of Broadcom semiconductor chipsets, achieved jury verdicts in favor of TQ Delta that defendant 2Wire, Inc. infringed two sets of patents relating to Digital Subscriber Line (DSL) patents, and that the patents were not invalid. Further liability trials are schedule for 2022. This is part of a series of related lawsuits against multiple defendants in which TQ Delta has asserted ten sets of patents from its DSL patent portfolio, which is the industry’s largest, comprising 29 patent families, 70 United States patents, 140 additional patents in other countries, and 65 patents pending worldwide.
“We are thrilled that Managing IP continues to recognize Robins Kaplan’s unique ability to take complex patent cases to the mat in both federal court and before the PTAB,” said Christopher Larus, Chair of the National IP and Technology Litigation Group.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.